Response to topical corticosteroid monotherapy in mycosis fungoides.
Administration, Cutaneous
Adult
Age Factors
Aged
Aged, 80 and over
Cross-Sectional Studies
Female
Glucocorticoids
/ administration & dosage
Humans
Male
Middle Aged
Mycosis Fungoides
/ diagnosis
Neoplasm Staging
Remission Induction
/ methods
Retrospective Studies
Severity of Illness Index
Sex Factors
Skin
/ pathology
Skin Neoplasms
/ diagnosis
Treatment Outcome
Young Adult
body surface area
cutaneous T-cell lymphoma
topical corticosteroid
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
19
11
2019
revised:
06
04
2020
accepted:
08
05
2020
pubmed:
20
5
2020
medline:
29
7
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Topical corticosteroids alone or in combination with other therapies are widely used to treat mycosis fungoides (MF), but data on response rates to their use as monotherapy in MF are limited. To evaluate the efficacy of topical corticosteroid monotherapy in MF; compare sex, age, stage distributions, and histopathologic features between responders and nonresponders. A retrospective cross-sectional review of patients with MF from 2013 to 2019 treated at Thomas Jefferson University was conducted. Patients with biopsy-proven MF, all stages, who received topical corticosteroid monotherapy were included. Response rates were determined by percent change in body surface area (BSA) involvement and modified Severity-Weighted Assessment Tool (mSWAT). Of the 163 patients with MF in our database, 23% (37/163) initially received topical steroid monotherapy. Of these, 73% (27/37) improved, with an average 65% decrease in BSA (67% in mSWAT); 27% (10/37) did not respond/progressed, with an average 51.6% increase in BSA (57% in mSWAT); and 33% (12/37) had a complete response (BSA, 0%) with prolonged topical steroid use. Early-stage MF and female sex were more represented in responders. Single-center retrospective design. Topical steroid monotherapy in early-stage MF can produce measurable improvements in BSA and mSWAT scores and achieve complete remission in a limited subset of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Topical corticosteroids alone or in combination with other therapies are widely used to treat mycosis fungoides (MF), but data on response rates to their use as monotherapy in MF are limited.
OBJECTIVE
OBJECTIVE
To evaluate the efficacy of topical corticosteroid monotherapy in MF; compare sex, age, stage distributions, and histopathologic features between responders and nonresponders.
METHODS
METHODS
A retrospective cross-sectional review of patients with MF from 2013 to 2019 treated at Thomas Jefferson University was conducted. Patients with biopsy-proven MF, all stages, who received topical corticosteroid monotherapy were included. Response rates were determined by percent change in body surface area (BSA) involvement and modified Severity-Weighted Assessment Tool (mSWAT).
RESULTS
RESULTS
Of the 163 patients with MF in our database, 23% (37/163) initially received topical steroid monotherapy. Of these, 73% (27/37) improved, with an average 65% decrease in BSA (67% in mSWAT); 27% (10/37) did not respond/progressed, with an average 51.6% increase in BSA (57% in mSWAT); and 33% (12/37) had a complete response (BSA, 0%) with prolonged topical steroid use. Early-stage MF and female sex were more represented in responders.
LIMITATIONS
CONCLUSIONS
Single-center retrospective design.
CONCLUSIONS
CONCLUSIONS
Topical steroid monotherapy in early-stage MF can produce measurable improvements in BSA and mSWAT scores and achieve complete remission in a limited subset of patients.
Identifiants
pubmed: 32428610
pii: S0190-9622(20)30908-7
doi: 10.1016/j.jaad.2020.05.043
pii:
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-623Informations de copyright
Copyright © 2020. Published by Elsevier Inc.